Medpace Holdings, Inc. $MEDP Stock Holdings Decreased by Argent Capital Management LLC

Key Points

• Argent Capital Management reduced its Medpace stake by 5.3% in the third quarter, selling 3,218 shares and retaining 56,996 shares worth approximately $35.6 million. Institutional investors collectively own 77.98% of MEDP.
• Medpace reported quarterly earnings of $4.25 per share, beating estimates of $3.98, while revenue rose 17.2% year over year to $707.33 million. The company set fiscal 2026 EPS guidance at $17.25–$17.95.
• MEDP shares recently traded at $616.70, near analysts’ consensus target of $602.27; the consensus rating remains “Hold.” CEO August Troendle also sold 21,966 shares for roughly $13.7 million, and insiders have sold about $208 million of stock over the past 90 days.

Argent Capital Management LLC lessened its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 5.3% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 56,996 shares of the company's stock after selling 3,218 shares during the period. Medpace accounts for approximately 0.3% of Argent Capital Management LLC's holdings, making the stock its 25th biggest position. Argent Capital Management LLC owned about 0.20% of Medpace worth $35,576,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of MEDP. American Capital Management Inc. purchased a new position in Medpace in the 2nd quarter worth approximately $111,329,000. Focus Partners Advisor Solutions LLC purchased a new stake in Medpace during the 2nd quarter valued at approximately $1,685,000. The Manufacturers Life Insurance Company bought a new stake in shares of Medpace during the second quarter valued at approximately $10,615,000. California State Teachers Retirement System raised its position in shares of Medpace by 22.1% during the first quarter. California State Teachers Retirement System now owns 26,042 shares of the company's stock valued at $12,505,000 after buying an additional 4,719 shares during the last quarter. Finally, BlackRock Inc. purchased a new position in shares of Medpace in the second quarter worth $1,323,047,000. 77.98% of the stock is owned by institutional investors.

Medpace Price Performance

Shares of NASDAQ MEDP traded up $17.23 during midday trading on Monday, reaching $616.70. 89,070 shares of the stock traded hands, compared to its average volume of 329,380. The company's 50 day moving average is $599.95 and its 200 day moving average is $521.65. Medpace Holdings, Inc. has a one year low of $373.00 and a one year high of $677.90. The stock has a market capitalization of $17.21 billion, a PE ratio of 36.08, a P/E/G ratio of 2.67 and a beta of 1.18.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company had revenue of $707.33 million for the quarter, compared to analysts' expectations of $689.51 million. During the same quarter in the previous year, the business posted $3.10 earnings per share. Medpace's quarterly revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, equities analysts forecast that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Insider Buying and Selling at Medpace

In other news, CEO August Troendle sold 21,966 shares of the company's stock in a transaction dated Wednesday, September 30th. The shares were sold at an average price of $625.47, for a total transaction of $13,739,074.02. Following the sale, the chief executive officer directly owned 338,225 shares in the company, valued at approximately $211,549,590.75. This represents a 6.10% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last 90 days, insiders have sold 336,140 shares of company stock valued at $208,008,328. Insiders own 20.50% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Mizuho upped their target price on shares of Medpace from $586.00 to $665.00 and gave the stock an "outperform" rating in a research report on Friday, July 24th. Jefferies Financial Group reiterated a "hold" rating on shares of Medpace in a research note on Monday, September 14th. Leerink Partners set a $620.00 price objective on shares of Medpace in a report on Thursday, July 23rd. TD Cowen raised their price objective on Medpace from $419.00 to $492.00 and gave the company a "hold" rating in a research report on Friday, July 24th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and issued a $535.00 target price on shares of Medpace in a report on Thursday, July 23rd. Three research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $602.27.

About Medpace

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the product development process, from early planning and protocol design through clinical trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance and regulatory consulting.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.